Recent submissions

  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

    Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-01-27)
    BACKGROUND:Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
  • From patent to patient: analysing access to innovative cancer drugs. 

    Sharpe, E; Hoey, R; Yap, C; Workman, P (2020-01-27)
    Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000-2016 shows that the number of authorisations increased over that timeframe. The median number of licensed drugs each year rose from 6 ...
  • Dosimetric accuracy of delivering SBRT using dynamic arcs on Cyberknife. 

    Bedford, JL; Nill, S; Oelfke, U (2020-02-12)
    PURPOSE:Several studies have demonstrated potential improvements in treatment time through the use of dynamic arcs for delivery of stereotactic body radiation therapy (SBRT) on Cyberknife. However, the delivery system has ...
  • Combining large scale in silico analysis with fragment screening to identify novel, ligandable secondary sites in cancer-associated proteins 

    Fletcher, C (2020-01-31)
    Proteins often have multiple binding sites involved in interactions with other molecules. The majority of currently approved drugs bind a protein's primary site, the major functional site in the protein. Targeting the ...
  • Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. 

    Patel, VL; Busch, EL; Friebel, TM; Cronin, A; Leslie, G; McGuffog, L; Adlard, J; Agata, S; Agnarsson, BA; Ahmed, M; Aittomäki, K; Alducci, E; Andrulis, IL; Arason, A; Arnold, N; Artioli, G; Arver, B; Auber, B; Azzollini, J; Balmaña, J; Barkardottir, RB; Barnes, DR; Barroso, A; Barrowdale, D; Belotti, M; Benitez, J; Bertelsen, B; Blok, MJ; Bodrogi, I; Bonadona, V; Bonanni, B; Bondavalli, D; Boonen, SE; Borde, J; Borg, A; Bradbury, AR; Brady, A; Brewer, C; Brunet, J; Buecher, B; Buys, SS; Cabezas-Camarero, S; Caldés, T; Caliebe, A; Caligo, MA; Calvello, M; Campbell, IG; Carnevali, I; Carrasco, E; Chan, TL; Chu, ATW; Chung, WK; Claes, KBM; Collaborators, GS; Collaborators, E; Cook, J; Cortesi, L; Couch, FJ; Daly, MB; Damante, G; Darder, E; Davidson, R; de la Hoya, M; Puppa, LD; Dennis, J; Díez, O; Ding, YC; Ditsch, N; Domchek, SM; Donaldson, A; Dworniczak, B; Easton, DF; Eccles, DM; Eeles, RA; Ehrencrona, H; Ejlertsen, B; Engel, C; Evans, DG; Faivre, L; Faust, U; Feliubadaló, L; Foretova, L; Fostira, F; Fountzilas, G; Frost, D; García-Barberán, V; Garre, P; Gauthier-Villars, M; Géczi, L; Gehrig, A; Gerdes, A-M; Gesta, P; Giannini, G; Glendon, G; Godwin, AK; Goldgar, DE; Greene, MH; Gutierrez-Barrera, AM; Hahnen, E; Hamann, U; Hauke, J; Herold, N; Hogervorst, FBL; Honisch, E; Hopper, JL; Hulick, PJ; Investigators, K; Investigators, H; Izatt, L; Jager, A; James, P; Janavicius, R; Jensen, UB; Jensen, TD; Johannsson, OT; John, EM; Joseph, V; Kang, E; Kast, K; Kiiski, JI; Kim, S-W; Kim, Z; Ko, K-P; Konstantopoulou, I; Kramer, G; Krogh, L; Kruse, TA; Kwong, A; Larsen, M; Lasset, C; Lautrup, C; Lazaro, C; Lee, J; Lee, JW; Lee, MH; Lemke, J; Lesueur, F; Liljegren, A; Lindblom, A; Llovet, P; Lopez-Fernández, A; Lopez-Perolio, I; Lorca, V; Loud, JT; Ma, ESK; Mai, PL; Manoukian, S; Mari, V; Martin, L; Matricardi, L; Mebirouk, N; Medici, V; Meijers-Heijboer, HEJ; Meindl, A; Mensenkamp, AR; Miller, C; Gomes, DM; Montagna, M; Mooij, TM; Moserle, L; Mouret-Fourme, E; Mulligan, AM; Nathanson, KL; Navratilova, M; Nevanlinna, H; Niederacher, D; Nielsen, FCC; Nikitina-Zake, L; Offit, K; Olah, E; Olopade, OI; Ong, K-R; Osorio, A; Ott, C-E; Palli, D; Park, SK; Parsons, MT; Pedersen, IS; Peissel, B; Peixoto, A; Pérez-Segura, P; Peterlongo, P; Petersen, AH; Porteous, ME; Pujana, MA; Radice, P; Ramser, J; Rantala, J; Rashid, MU; Rhiem, K; Rizzolo, P; Robson, ME; Rookus, MA; Rossing, CM; Ruddy, KJ; Santos, C; Saule, C; Scarpitta, R; Schmutzler, RK; Schuster, H; Senter, L; Seynaeve, CM; Shah, PD; Sharma, P; Shin, VY; Silvestri, V; Simard, J; Singer, CF; Skytte, A-B; Snape, K; Solano, AR; Soucy, P; Southey, MC; Spurdle, AB; Steele, L; Steinemann, D; Stoppa-Lyonnet, D; Stradella, A; Sunde, L; Sutter, C; Tan, YY; Teixeira, MR; Teo, SH; Thomassen, M; Tibiletti, MG; Tischkowitz, M; Tognazzo, S; Toland, AE; Tommasi, S; Torres, D; Toss, A; Trainer, AH; Tung, N; van Asperen, CJ; van der Baan, FH; van der Kolk, LE; van der Luijt, RB; van Hest, LP; Varesco, L; Varon-Mateeva, R; Viel, A; Vierstrate, J; Villa, R; von Wachenfeldt, A; Wagner, P; Wang-Gohrke, S; Wappenschmidt, B; Weitzel, JN; Wieme, G; Yadav, S; Yannoukakos, D; Yoon, S-Y; Zanzottera, C; Zorn, KK; D'Amico, AV; Freedman, ML; Pomerantz, MM; Chenevix-Trench, G; Antoniou, AC; Neuhausen, SL; Ottini, L; Nielsen, HR; Rebbeck, TR (2020-02)
    Pathogenic sequence variants (PSV) in BRCA1 or BRCA2 (BRCA1/2) are associated with increased risk and severity of prostate cancer. We evaluated whether PSVs in BRCA1/2 were associated with risk of overall prostate cancer ...
  • Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. 

    Mavaddat, N; Antoniou, AC; Mooij, TM; Hooning, MJ; Heemskerk-Gerritsen, BA; GENEPSO; Noguès, C; Gauthier-Villars, M; Caron, O; Gesta, P; Pujol, P; Lortholary, A; EMBRACE; Barrowdale, D; Frost, D; Evans, DG; Izatt, L; Adlard, J; Eeles, R; Brewer, C; Tischkowitz, M; Henderson, A; Cook, J; Eccles, D; HEBON; van Engelen, K; Mourits, MJE; Ausems, MGEM; Koppert, LB; Hopper, JL; John, EM; Chung, WK; Andrulis, IL; Daly, MB; Buys, SS; kConFab Investigators; Benitez, J; Caldes, T; Jakubowska, A; Simard, J; Singer, CF; Tan, Y; Olah, E; Navratilova, M; Foretova, L; Gerdes, A-M; Roos-Blom, M-J; Van Leeuwen, FE; Arver, B; Olsson, H; Schmutzler, RK; Engel, C; Kast, K; Phillips, K-A; Terry, MB; Milne, RL; Goldgar, DE; Rookus, MA; Andrieu, N; Easton, DF; IBCCS; kConFab; BCFR (2020-01-16)
    BACKGROUND:The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially ...
  • Genomics of lethal prostate cancer at diagnosis and castration-resistance. 

    Mateo, J; Seed, G; Bertan, C; Rescigno, P; Dolling, D; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Gurel, B; Clarke, M; Atkin, M; Chandler, R; Messina, C; Sumanasuriya, S; Bianchini, D; Barrero, M; Petremolo, A; Zafeiriou, Z; Fontes, MS; Perez-Lopez, R; Tunariu, N; Fulton, BA; Jones, R; McGovern, UB; Ralph, C; Varughese, M; Parikh, O; Jain, S; Elliott, T; Sandhu, S; Porta, N; Hall, E; Yuan, W; Carreira, S; de Bono, JS (2019-12-24)
    Genomics of primary prostate cancer differs from that of metastatic castration-resistant prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer biopsies from patients who developed mCRPC, also ...
  • Health-related quality of life around the time of diagnosis in patients with bladder cancer. 

    Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; Bryan, RT; Wesselius, A; Zeegers, MP (2019-12)
    OBJECTIVES:To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire QLQ-C30. METHODS:From ...
  • Measuring tumour evolution at the genetic and epigenetic level in individual patients from cancer genomic data 

    Chkhaidze, K (2020-01-31)
    High-throughput genomic data from cancers uncovered high intra and inter-tumour heterogeneity and subclonal architecture of cancer cell populations. If we consider cells as asexually reproducing individuals, we can apply ...
  • The risk of ovarian cancer increases with an increase in the lifetime number of ovulatory cycles: an analysis from the Ovarian Cancer Cohort Consortium (OC3). 

    Trabert, B; Tworoger, SS; O'Brien, KM; Townsend, MK; Fortner, RT; Iversen, ES; Hartge, P; White, E; Amiano, P; Arslan, AA; Bernstein, L; Brinton, LA; Buring, JE; Dossus, L; Fraser, GE; Gaudet, MM; Giles, GG; Gram, IT; Harris, HR; Hoffman Bolton, J; Idahl, A; Jones, ME; Kaaks, R; Kirsh, VA; Knutsen, SF; Kvaskoff, M; Lacey, JV; Lee, I-M; Milne, RL; Onland-Moret, NC; Overvad, K; Patel, AV; Peters, U; Poynter, JN; Riboli, E; Robien, K; Rohan, TE; Sandler, DP; Schairer, C; Schouten, LJ; Setiawan, VW; Swerdlow, AJ; Travis, RC; Trichopoulou, A; van den Brandt, PA; Visvanathan, K; Wilkens, LR; Wolk, A; Zeleniuch-Jacquotte, A; Wentzensen, N (2020-01-13)
    Repeated exposure to the acute pro-inflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, ...
  • Optimising trial methodologies to maximise trial efficiencies: a case study in breast cancer radiotherapy trials 

    Bhattacharya, I (2020-01-31)
    Background: In an era of falling local relapse rates, the risk-benefit ratio of adjuvant breast radiotherapy requires careful consideration, and the collection of normal tissue effect (NTE) data optimised. For patients at ...
  • Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation. 

    Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; Dearnaley, D; Gulliford, S; CHHiP Trial Management Group (2020-01-24)
    BACKGROUND:The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based ...
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. 

    Allison, KH; Hammond, MEH; Dowsett, M; McKernin, SE; Carey, LA; Fitzgibbons, PL; Hayes, DF; Lakhani, SR; Chavez-MacGregor, M; Perlmutter, J; Perou, CM; Regan, MM; Rimm, DL; Symmans, WF; Torlakovic, EE; Varella, L; Viale, G; Weisberg, TF; McShane, LM; Wolff, AC (2020-01-13)
    PURPOSE:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS:A multidisciplinary ...
  • Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. 

    Allison, KH; Hammond, MEH; Dowsett, M; McKernin, SE; Carey, LA; Fitzgibbons, PL; Hayes, DF; Lakhani, SR; Chavez-MacGregor, M; Perlmutter, J; Perou, CM; Regan, MM; Rimm, DL; Symmans, WF; Torlakovic, EE; Varella, L; Viale, G; Weisberg, TF; McShane, LM; Wolff, AC (2020-01-13)
    PURPOSE.—:To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS.—:A ...
  • Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial. 

    Murray, J; Gulliford, S; Griffin, C; Wilkins, A; Syndikus, I; Staffurth, J; Panades, M; Scrase, C; Parker, C; Khoo, V; Dean, J; Mayles, H; Mayles, P; Thomas, S; Naismith, O; Mossop, H; Cruickshank, C; Hall, E; Dearnaley, D; CHHiP Investigators (2020-03)
    Background and purpose:The penile bulb (PB) dose may be critical in development of post prostate radiotherapy erectile dysfunction (ED). This study aimed to generate PB dose constraints based on dose-volume histograms ...
  • The PERK inhibitor GSK2606414 enhances reovirus infection in head and neck squamous cell carcinoma via an ATF4-dependent mechanism 

    McLaughlin, M; Pedersen, M; Roulstone, V; Bergerhoff, KF; Smith, HG; Whittock, H; Kyula, J; Dillon, MT; Pandha, H; Vile, R; Melcher, A; Harrington, KJ
  • Seven or less Fractions is Not the Standard of Care for Intermediate-Risk Prostate Cancer. 

    Tree, AC; Dearnaley, DP (2020-03)
    Evidence is accumulating for seven and less fractions in localised prostate cancer, including one large randomised trial. However, there is much more evidence yet to come and changing practice in advance of this may be ...
  • Measuring Clonal Evolution in Cancer with Genomics. 

    Williams, MJ; Sottoriva, A; Graham, TA (2019-08)
    Cancers originate from somatic cells in the human body that have accumulated genetic alterations. These mutations modify the phenotype of the cells, allowing them to escape the homeostatic regulation that maintains normal ...
  • Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. 

    Shu, X; Wu, L; Khankari, NK; Shu, X-O; Wang, TJ; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Milne, RL; Schmidt, MK; Pharoah, PDP; Andrulis, IL; Hunter, DJ; Simard, J; Easton, DF; Zheng, W; Breast Cancer Association Consortium (2019-06)
    BACKGROUND:In addition to the established association between general obesity and breast cancer risk, central obesity and circulating fasting insulin and glucose have been linked to the development of this common malignancy. ...
  • Evaluation of dysphagia-optimising radiotherapy techniques in locally advanced oropharyngeal cancer 

    Petkar, I (2020-01-31)
    Radiation-associated dysphagia (RAD) following chemoradiation in locally advanced oropharyngeal cancers (LA-OPC) can have a devastating impact on patients' quality of life (QoL). Establishing efficient swallow-sparing ...

View more